Dr. Pin Wang co-founded Simnova Bio in 2020 and has since served as Chief Scientific Officer and Interim Chief Executive Officer. Prior to starting at Simnova Bio, Dr. Wang was Chief Scientific Officer of Simcere Pharmaceutical Group and was responsible for the R&D of cell therapy business unit and the management of Boston R&D center. Dr. Wang spent most of his time in academia before joining industry. He established his own research group at the University of Southern California (USC) in 2005 and started as an Assistant Professor there and eventually became a Zohrab A. Kaprelian Fellow and Professor of Chemical Engineering and Materials Science, Biomedical Engineering, and Pharmaceutical Sciences and Pharmacology. Dr. Wang also founded the Center for ImmunoEngineering at USC and focused on research aiming to employ engineering tools and principles to quantitively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses.
Dr. Wang graduated with a bachelor’s degree in Macromolecular Physics from the University of Science and Technology of China and obtained a PhD in Chemical Engineering from California Institute of Technology. Many technology discoveries from Dr. Wang’s research career enabled formation of several biotech companies such as Immune Design Corp. (acquired by Merck), TCRCure Biopharma, Appia Bio, etc.